Loading...
Market
Story
FDA Approves Merck’s Keytruda with Chemotherapy for Advanced Mesothelioma
Sep 18, 2024, 10:48 AM
The FDA has approved Merck’s Keytruda (pembrolizumab) in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This FDA approval marks a significant advancement for patients suffering from this rare and aggressive form of lung cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Yes • 50%
No • 50%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
